BioMarin Pharmaceutical's (BMRN) Roctavian Resubmittal Date Pushed Out to September - Credit Suisse
Tweet Send to a Friend
Credit Suisse analyst Martin Auster reiterated an Outperform rating and $105.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
